These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31325043)

  • 1. Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort.
    Peikert A; Kaier K; Merz J; Manhart L; Schäfer I; Hilgendorf I; Hehn P; Wolf D; Willecke F; Sheng X; Clemens A; Zehender M; von Zur Mühlen C; Bode C; Zirlik A; Stachon P
    Clin Res Cardiol; 2020 Mar; 109(3):315-323. PubMed ID: 31325043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
    Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial.
    Ridker PM; MacFadyen JG; Glynn RJ; Bradwin G; Hasan AA; Rifai N
    Eur Heart J; 2020 Aug; 41(31):2952-2961. PubMed ID: 32221587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
    Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
    Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.
    Hwang YC; Morrow DA; Cannon CP; Liu Y; Bergenstal R; Heller S; Mehta C; Cushman W; Bakris GL; Zannad F; White WB
    Diabetes Obes Metab; 2018 Mar; 20(3):654-659. PubMed ID: 29064626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divergence of Cardiovascular Biomarkers of Lipids and Subclinical Myocardial Injury Among Rheumatoid Arthritis Patients With Increased Inflammation.
    Weber B; He Z; Yang N; Playford MP; Weisenfeld D; Iannaccone C; Coblyn J; Weinblatt M; Shadick N; Di Carli M; Mehta NN; Plutzky J; Liao KP
    Arthritis Rheumatol; 2021 Jun; 73(6):970-979. PubMed ID: 33615723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention.
    Guedeney P; Claessen BE; Kalkman DN; Aquino M; Sorrentino S; Giustino G; Farhan S; Vogel B; Sartori S; Montalescot G; Sweeny J; Kovacic JC; Krishnan P; Barman N; Dangas G; Kini A; Baber U; Sharma S; Mehran R
    J Am Coll Cardiol; 2019 May; 73(19):2401-2409. PubMed ID: 31097159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
    De Ferrari GM; Perna GP; Nicosia A; Guasti L; Casu G; Cuccia C; Picco F; Strazzella C; Totaro R; Cercone S; Canullo L; Horack M; Lautsch D; Gitt AK; Di Biase M
    J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):485-490. PubMed ID: 29917002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin Therapy.
    Hyun MH; Lee Y; Choi BG; Na JO; Choi CU; Kim JW; Kim EJ; Rha SW; Park CG; Lee E; Seo HS
    Cardiovasc Ther; 2019; 2019():3824823. PubMed ID: 31885691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation.
    Dagli N; Yavuzkir M; Karaca I
    Inflammation; 2007 Dec; 30(6):230-5. PubMed ID: 17687635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event.
    Munkhaugen J; Otterstad JE; Dammen T; Gjertsen E; Moum T; Husebye E; Gullestad L
    Eur J Prev Cardiol; 2018 Jun; 25(9):923-931. PubMed ID: 29635941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy.
    Ridker PM; Tuttle KR; Perkovic V; Libby P; MacFadyen JG
    Eur Heart J; 2022 Dec; 43(46):4832-4844. PubMed ID: 35943897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Value of Baseline High-Sensitivity C-Reactive Protein Level and Renal Function for Patients With Acute Coronary Syndrome Undergoing Aggressive Lipid-Lowering Therapy: A Subanalysis of HIJ-PROPER.
    Kawada-Watanabe E; Yamaguchi J; Kanbayashi K; Sekiguchi H; Arashi H; Ogawa H; Hagiwara N
    Am J Cardiol; 2018 Dec; 122(11):1817-1823. PubMed ID: 30270178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
    Koenig W
    Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identical LDL-cholesterol lowering but non-identical effects on NF-κB activity: High dose simvastatin vs combination therapy with ezetimibe.
    Rudofsky G; Reismann P; Groener JB; Djuric Z; Fleming T; Metzner C; Grafe IA; Bierhaus A; Nawroth PP
    Atherosclerosis; 2012 Jul; 223(1):190-6. PubMed ID: 22633472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease.
    von Eynatten M; Hamann A; Twardella D; Nawroth PP; Brenner H; Rothenbacher D
    Clin Chem; 2006 May; 52(5):853-9. PubMed ID: 16556684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    Carter NJ
    Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol.
    Kanadaşi M; Cayli M; Demirtaş M; Inal T; Demir M; Koç M; Avkaroğullari M; Dönmez Y; Usal A; Alhan CC; San M
    Heart Vessels; 2006 Sep; 21(5):291-7. PubMed ID: 17151816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.